Drug Houses of Australia (Asia) Pte Ltd.
Drug Houses of Australia (Asia) Pte Ltd., commonly referred to as DHA, is a prominent player in the pharmaceutical industry, headquartered in Singapore. Established in 1990, the company has expanded its operations across key regions in Asia, focusing on the development and distribution of high-quality pharmaceutical products. DHA is renowned for its commitment to innovation, offering a diverse range of prescription medications, over-the-counter products, and healthcare solutions. What sets DHA apart is its rigorous quality control processes and adherence to international standards, ensuring the safety and efficacy of its offerings. With a strong market position, DHA has achieved significant milestones, including strategic partnerships and a robust distribution network. The company continues to be a trusted name in the healthcare sector, dedicated to improving patient outcomes across the region.
DitchCarbon Score
How does Drug Houses of Australia (Asia) Pte Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Drug Houses of Australia (Asia) Pte Ltd.'s score of 35 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Drug Houses of Australia (Asia) Pte Ltd.'s reported carbon emissions
Drug Houses of Australia (Asia) Pte Ltd., headquartered in Singapore (SG), currently does not have any publicly available carbon emissions data for the most recent year. As a result, specific figures regarding their carbon footprint, including Scope 1, 2, or 3 emissions, are not provided. In the absence of emissions data, it is important to note that the company has not outlined any specific reduction targets or initiatives related to carbon emissions. There are no commitments to the Science Based Targets initiative (SBTi) or any climate pledges mentioned, indicating a potential area for future development in their sustainability strategy. As the industry increasingly prioritises climate action, Drug Houses of Australia (Asia) Pte Ltd. may benefit from establishing clear emissions reduction goals and transparent reporting practices to align with global climate commitments.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Drug Houses of Australia (Asia) Pte Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
